Nucleic Acid Amplification Testing (NAAT) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
The nucleic acid amplification testing (NAAT) market was valued at approximately USD 2,985 million in 2020, and it is projected to reach USD 4,745 million by 2026, registering a CAGR of nearly 8% during the forecast period, 2021-2026.
The current recommended condition for the detection of a potent or current SARS-CoV-2 infection is a nucleic acid amplification (NAAT) test that detects targeted one or more specific RNA specific strains of the virus. Patients with symptoms, people with known or suspected COVID-19 exposure, and people from high-risk areas can be tested in this way. The Manohar Parrikar Institute for Defence Studies and Analyses guidelines also suggest that patients who first diagnosed negative, but where there is high clinical suspicion of COVID-19, should receive additional NAAT, which is estimated to increase sensitivity to testing by 17%; hence, the demand for these tests increased during the pandemic.
The major factors for the growth of the nucleic acid amplification testing (NAAT) market include the rising prevalence of infectious diseases, increasing demand for advanced diagnostic measures, and rising investment for the development of new biotechnological diagnostic techniques.
NAAT detects certain nucleic acids, viruses, or bacteria that act as pathogens in the blood, tissues, urine, etc. In addition, this method is also used to screen blood donations to reduce the risk of blood transfusion infection in recipients. Also, there is a growing increase in various infectious diseases that are expected to drive the market in the forecast period.
NAAT detects particular nucleic acid, virus, or bacteria, which acts as a pathogen in blood, tissue, urine, etc. Furthermore, this technique is also used for screening blood donations to reduce the risk of transfusion-transmitted infections in recipients. Also, there is a rising prevalence of various infectious diseases, which is expected to boost the market over the forecast period.
As per the Avert, in 2020, several Asian countries were facing a rapid rise in the HIV epidemic. For example, the Philippines was experiencing the maximum rise with many new infections. In addition, the estimated HIV prevalence rates in cities, such as Bangkok in Thailand, Yangon in Myanmar, and Yogyakarta in Indonesia, were between 20% and 29%. These factors draw the attention of NAAT detection tests into consideration.
As per the International Agency for Research on Cancer (IARC), in December 2020, globally, 1 in 5 persons develops cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. The IARC estimated that in 2020, the prevalence of cancer rose to 19.3 million cases and 10 million cancer deaths, which was around 18 million cancer cases around the world in 2018. With this growing burden, the NAAT procedures are increasing in demand due to their sensitivity.
According to recent studies, on average, 10% of patients with coronavirus infections may be missed with PCR tests that are diagnosed by NAAT. The accuracy of tests for coronavirus diagnosis is important for patient management and epidemic control. Hence, the usage of these tests has grown during the pandemic period and so did the infectious diseases segment.
The major factor driving the growth of the segment is the rising prevalence of various infectious diseases across the globe. For instance, as per the WHO in 2019, an estimated 10 million people were affected with tuberculosis (TB) globally, which included 5.6 million men, 3.2 million women, and 1.2 million children.
According to the hepatitis foundation, 2021, 2 billion people have been infected with the hepatitis B virus and 30 million people become newly infected each year, and an estimated 884,000 people die each year from hepatitis B and related complications such as liver cancer. With this severity of the disease, there is a need and demand for diagnostic tests that are more reliable and sensitive, and thus, the demand for NAAT is growing.
NAAT is generally clear and very sensitive and can be used for all stages of infection. Recent advances have led to many trials. In a multiplex test, a single nucleic acid-based test can detect and differentiate between more than two microorganisms. Thus, owing to all the above-mentioned factors, the market is expected to witness high growth over the forecast period.
The United States is expected to be the largest nucleic acid amplification testing market owing to the presence of better healthcare infrastructure and the rising prevalence of infectious diseases.
In Canada, Canadian Blood Services has implemented NAAT and provides a safe blood supply by detecting low levels of viral genes. These programs increase the use of these tests. Furthermore, NAAT is becoming the standard of practice in the blood and plasma industry in the United States and around the world.
According to the estimates of the American Cancer Society, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the United States, and 606,520 people died from the disease. Moreover, 1,735,350 new cancer cases diagnosed and 609,640 deaths in 2018. The growing cancer burden is increasing the need for diagnostic tests like NAAT.
According to Hepatitis Foundation, 2021, up to 2.2 million people are chronically infected with HepB, but only 25% of infected individuals are diagnosed. Therefore, there is an increasing need for better diagnostic tests in the regions, and hence, the major players and the government are focusing on NAAT.
Thus, considering all the above-mentioned factors, the market is expected to witness high growth.
The market studied is a consolidated market owing to the presence of few major market players. Some of the market players are Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories Inc., Grifols SA, Hoffmann-La Roche Ltd, Hologic Inc., and Illumina Inc.